Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Alnylam Pharmaceuticals
(NQ:
ALNY
)
172.92
USD
-2.77 (-1.58%)
Streaming Delayed Price
Updated: 3:23 PM EST, Jan 26, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Alnylam Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
45
46
Next >
Alnylam Launches “Alnylam P5x25” Strategy for Planned Transition to a Top Five Biotech in Market Capitalization Over Next Five Years
January 10, 2021
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its new 5-year strategy “Alnylam P5x25” focused on the Company’s planned transition to a top-5...
From
Business Wire News Releases
Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
January 07, 2021
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development...
From
Business Wire News Releases
Alnylam to Webcast Presentation at 39th Annual J.P. Morgan Healthcare Conference
January 04, 2021
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 39th Annual J.P. Morgan Healthcare Conference...
From
Business Wire News Releases
Alnylam Appoints Tolga Tanguler Chief Commercial Officer and Also Announces New CEMEA, Medical Affairs, and Compliance Leaders
December 21, 2020
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the appointment of Tolga Tanguler to the role of Chief Commercial Officer where he will lead global...
From
Business Wire News Releases
Alnylam Announces 2021 Product and Pipeline Goals and Provides Program Updates at R&D Day
December 15, 2020
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is kicking off a virtual R&D Day event today. During the two-day event, the Company plans to showcase its commercial...
From
Business Wire News Releases
Alnylam to Webcast Virtual R&D Day
December 08, 2020
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming virtual R&D Day event on the Investors section of the Company’s...
From
Business Wire News Releases
CENTOGENE and Alnylam Pharmaceuticals Launch a New Clinical Program Aimed at Revolutionizing the Diagnosis of Hereditary Transthyretin-Related Amyloidosis (“ATTRv”)
December 08, 2020
From
GlobeNewswire News Releases
Alnylam Issues 2nd Annual Patient Access Philosophy Report Highlighting Broad Access to the Company’s Approved Therapies
December 07, 2020
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today published two new reports: the second annual update on its Patient Access Philosophy and its first-ever Rare...
From
Business Wire News Releases
PANTHERx Rare® Pharmacy Chosen as Partner by Alnylam Pharmaceuticals for OXLUMO™ (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary Oxalate Levels
December 03, 2020
PANTHERx® Rare Pharmacy announces that it has been selected by Alnylam Pharmaceuticals, the leading RNAi therapeutics company, as a very limited distribution pharmacy partner for new drug OXLUMO™...
From
PR Newswire
Orsini Specialty Pharmacy Expands Partnership With Alnylam® Pharmaceuticals As A Limited Distribution Partner For OXLUMO™ (lumasiran)
December 03, 2020
Orsini Specialty Pharmacy, a leader in rare diseases and gene therapies, announced today that it has been selected by Alnylam® Pharmaceuticals as a limited distribution partner for OXLUMO™ (lumasiran)....
From
PR Newswire
Alnylam Completes Enrollment in ILLUMINATE-C Phase 3 Study of Lumasiran, an RNAi Therapeutic, for the Treatment of Advanced Primary Hyperoxaluria Type 1
December 03, 2020
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has achieved full patient enrollment in its ILLUMINATE-C Phase 3 study of lumasiran, an RNAi...
From
Business Wire News Releases
Alnylam to Webcast Presentation at 43rd Nasdaq Virtual Investor Conference
November 25, 2020
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 43rd Nasdaq Virtual Investor Conference on...
From
Business Wire News Releases
Alnylam Announces Innovative Value-Based Agreement Framework for OXLUMO™ (lumasiran) to Accelerate Access for Patients with Primary Hyperoxaluria Type 1 and Deliver Ultra-Rare Orphan Disease Pricing S
November 24, 2020
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today a new framework for value-based agreements (VBAs) designed to help people with primary hyperoxaluria...
From
Business Wire News Releases
Alnylam Announces U.S. Food and Drug Administration (FDA) Approval of OXLUMO™ (lumasiran), the First and Only Treatment Approved for Primary Hyperoxaluria Type 1 to Lower Urinary Oxalate Levels in Ped
November 24, 2020
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) approved OXLUMO™ (lumasiran) injection for...
From
Business Wire News Releases
Alnylam Receives Approval for OXLUMO™ (lumasiran) in the European Union for the Treatment of Primary Hyperoxaluria Type 1 in All Age Groups
November 19, 2020
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the European Commission (EC) has granted marketing authorization for OXLUMO™ (lumasiran), an...
From
Business Wire News Releases
Alnylam Reports Positive Interim Results from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension
November 13, 2020
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive interim data from the ongoing Phase 1 study of ALN-AGT, a subcutaneous investigational RNAi...
From
Business Wire News Releases
Alnylam Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Recent Period Activity
November 05, 2020
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter 2020 and reviewed recent business...
From
Business Wire News Releases
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
November 02, 2020
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences being held virtually:
From
Business Wire News Releases
Alnylam Wins Prestigious Prix Galien Award for Best Biotechnology Product with First-Ever Approved RNAi Therapeutic, ONPATTRO® (patisiran)
October 30, 2020
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it has won the 2020 Prix Galien USA Award for Best Biotechnology Product for ONPATTRO® (patisiran)....
From
Business Wire News Releases
Alnylam Named a Top Biopharma Employer by Science Magazine
October 29, 2020
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that, for the second year in a row, Science magazine has named the company a top employer in its...
From
Business Wire News Releases
Alnylam to Webcast Conference Call Discussing Third Quarter 2020 Financial Results
October 22, 2020
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2020 on Thursday,...
From
Business Wire News Releases
Alnylam Presents Positive Results from ILLUMINATE-B Phase 3 Study in Pediatric Patients with Primary Hyperoxaluria Type 1 at the American Society of Nephrology Kidney Week
October 22, 2020
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive results from the 6-month primary analysis of the ILLUMINATE-B Phase 3 pediatric study of...
From
Business Wire News Releases
Alnylam Receives Positive CHMP Opinion for OXLUMO™ (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 in All Age Groups
October 16, 2020
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...
From
Business Wire News Releases
Vir and Alnylam to Webcast Virtual Fireside Chat at H.C. Wainwright Hepatitis B Virus Mini-Conference
October 13, 2020
From
GlobeNewswire News Releases
Alnylam Reports Positive Topline Results from ILLUMINATE-B Phase 3 Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 in Children Under the Age of Six
September 30, 2020
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive topline results from the ILLUMINATE-B pediatric Phase 3 study of lumasiran, an...
From
Business Wire News Releases
Alnylam to Webcast Presentation at Chardan Virtual 4th Annual Genetic Medicines Conference
September 28, 2020
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Chardan Virtual 4th Annual Genetic Medicines...
From
Business Wire News Releases
Alnylam Highlights Prospects for Building an Industry-Leading ATTR Amyloidosis Franchise at RNAi Roundtable
September 03, 2020
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, will host an “RNAi Roundtable” webinar today at 12:00 p.m. ET, which will focus on progress across its ATTR...
From
Business Wire News Releases
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
September 02, 2020
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences being held virtually:
From
Business Wire News Releases
Blackstone and Alnylam Close $150 Million R&D Financing to Advance RNAi Therapeutics for Cardiovascular Disease
August 17, 2020
Blackstone (NYSE: BX) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the closing of the R&D funding component of the companies’ previously...
From
Business Wire News Releases
Alnylam Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent Period Activity
August 06, 2020
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2020 and reviewed recent business...
From
Business Wire News Releases
< Previous
1
2
3
4
5
6
7
8
9
...
45
46
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.